Biopharmaceutical company Cephalon ( CEPH) posted a second-quarter profit on higher-than-expected sales Monday after the close, as total company revenue increased 115% from the year-ago quarter. Cephalon said it earned $14.4 million, or 25 cents a share, in the quarter, compared with a year-ago loss of $9.3 million, or 19 cents a share, excluding an extraordinary gain. Analysts polled by tracking firm Thomson Financial/First Call had been looking for 21 cents. Despite the solid results, shares were recently down about 5% to $40.75 in premarket trading. Total revenue was $120.7 million, up from $56.2 million last year and ahead of the consensus estimate of $111.68 million. Total product sales were $108.8 million, up from $44.3 million last year, led by sales of cancer painkiller ACTIQ, which increased 192% to $28.5 million. Looking ahead, the company raised its full-year guidance on the "exceptionally strong sales of ACTIQ," saying it now expects to earn $1.08 to $1.10 a share on product sales of $430 million to $435 million. Previously, Cephalon had forecast $1.05 to $1.08 a share on sales of $415 million to $420 million. For the third quarter, the company expects to earn 27 cents a share on sales of $110 million to $115 million. First Call analysts are looking for $1.08 for the year and 27 cents for the third quarter.